Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Position Lifted by Stifel Financial Corp

Stifel Financial Corp raised its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 99.3% in the 3rd quarter, Holdings Channel.com reports. The firm owned 37,207 shares of the biotechnology company’s stock after acquiring an additional 18,537 shares during the period. Stifel Financial Corp’s holdings in Sarepta Therapeutics were worth $4,647,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Fifth Third Wealth Advisors LLC acquired a new position in Sarepta Therapeutics in the second quarter worth about $607,000. Teachers Retirement System of The State of Kentucky acquired a new position in shares of Sarepta Therapeutics in the 2nd quarter worth approximately $4,771,000. Simplify Asset Management Inc. increased its holdings in shares of Sarepta Therapeutics by 84.6% in the 3rd quarter. Simplify Asset Management Inc. now owns 193,010 shares of the biotechnology company’s stock valued at $24,105,000 after acquiring an additional 88,474 shares during the last quarter. Summit Partners Public Asset Management LLC increased its holdings in shares of Sarepta Therapeutics by 547.9% in the 3rd quarter. Summit Partners Public Asset Management LLC now owns 138,118 shares of the biotechnology company’s stock valued at $17,250,000 after acquiring an additional 116,800 shares during the last quarter. Finally, Natixis Advisors LLC acquired a new stake in shares of Sarepta Therapeutics during the 2nd quarter valued at approximately $1,918,000. Institutional investors and hedge funds own 86.68% of the company’s stock.

Analyst Ratings Changes

A number of research firms have commented on SRPT. Needham & Company LLC decreased their price objective on shares of Sarepta Therapeutics from $205.00 to $202.00 and set a “buy” rating for the company in a report on Wednesday, November 27th. HC Wainwright decreased their price target on shares of Sarepta Therapeutics from $80.00 to $75.00 and set a “sell” rating for the company in a report on Tuesday, December 3rd. William Blair upgraded shares of Sarepta Therapeutics to a “strong-buy” rating in a research note on Friday, August 30th. Piper Sandler decreased their target price on Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating for the company in a research note on Wednesday, November 27th. Finally, Jefferies Financial Group assumed coverage on Sarepta Therapeutics in a report on Monday, October 21st. They set a “buy” rating and a $165.00 target price for the company. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $178.71.

Insider Activity

In other news, Director Kathryn Jean Boor sold 1,636 shares of the company’s stock in a transaction on Thursday, December 5th. The stock was sold at an average price of $125.55, for a total value of $205,399.80. Following the completion of the sale, the director now owns 5,880 shares in the company, valued at $738,234. This represents a 21.77 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Stock Down 0.6 %

Sarepta Therapeutics stock opened at $123.71 on Monday. Sarepta Therapeutics, Inc. has a 52 week low of $89.92 and a 52 week high of $173.25. The stock has a market cap of $11.82 billion, a price-to-earnings ratio of 98.97 and a beta of 0.77. The company’s 50-day moving average price is $123.12 and its two-hundred day moving average price is $131.53. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.